Navigation Links
New therapy to stop progression of fibrosis
Date:2/14/2014

Scientists from the University of Sheffield have developed a novel antibody-based therapy which targets the progression of life threating kidney fibrosis.

The ground breaking therapy works by blocking the action of a key enzyme and the treatment should also work for lung, liver and heart fibrosis.

The pioneering biological discovery was made by a research team led by Professor Tim Johnson and Dr Phil Watson, from the University's Academic Nephrology Unit in the Department of Infection and Immunity.

The research, conducted in collaboration with MRC Technology, targets a key step in the progression of fibrosis, which has led to the development of a fibrosis therapy programme and exclusive licensing agreement by global biopharmaceutical company UCB.

There is currently no cure for fibrosis, a primary cause of major organ failure, and a complicating factor in chronic diseases such as diabetes and hypertension.

Professor Johnson said: "The development of these therapeutic antibodies is the culmination of 20 years work to identify the role of a key target in the tissue scarring process where it is possible to understand its mechanism of action and then develop a way to specifically target it.

"This is a fantastic example of how MRC Technology can assist in translating laboratory research to the patient. I am delighted that UCB have licensed the humanised antibodies as the company's expertise in antibody development will ensure patients benefit from this new treatment in the shortest time possible."

He added: " It is also extremely important to recognise that this work would not have been possible without support from charities such as Kidney Research UK, Diabetes UK and the Wellcome trust who have all supported this work."

UCB New Medicines Vice President and Head of Immunology, Dr Mark Bodmer, said: "The program focuses on a key area of unmet medical need and we are committed to bringing fibrosis treatment to patients.

"We are excited to be working with MRC Technology and University of Sheffield scientists to build on their work to date in generating and characterising promising therapeutic approaches with the potential for significant patient impact."

Michael Dalrymple, Director of Business Development at MRC Technology, said: "We are delighted to be able to partner this program with UCB and we look forward to working together to ensure the project's commercial success. This program has the potential to not only benefit fibrosis patients and help prevent organ failure, but also enables MRC Technology and its partners to help bring other new research to market."

Revenue made from the licensing agreement will be shared back with the University and will be reinvested to support other collaborative programs within its drug discovery labs.


'/>"/>

Contact: Amy Pullan
a.l.pullan@sheffield.ac.uk
01-142-229-859
University of Sheffield
Source:Eurekalert

Related medicine news :

1. Metal implants may cut chemotherapy side effects, study suggests
2. LA BioMed researchers report on promising new therapy for devastating genetic disorder
3. Skin reactions during radiation therapy preventable
4. What is the safest way to stop postmenopausal hormone therapy?
5. Cancer immunotherapy leader Allison to receive 2014 Szent-Gyorgyi Prize
6. Endocrine Society calls for large-scale studies to evaluate testosterone therapy risks
7. The art and science of cognitive rehabilitation therapy
8. Researchers open door to new HIV therapy
9. Music therapys positive effects on young cancer patients coping skills, social integration
10. Long-term follow-up shows need for new chemotherapy strategies for rectal cancer
11. Dr. Leigh Ann Scott to Open Irving Office to Provide Bio-Identical Hormone Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 13, 2016 , ... Valentine’s Day is nearly upon us, and most singles ... great outfit, flawless hair, and a sparkling personality are all well and good, but ... night at home with Rover. (Actually, man’s best friend might not even want to ...
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a healthy lifestyle ... reasons. IsoPasta by Isolator Fitness has delved into this niche allowing those giving ... high-carb repercussions. IsoPasta has 30 grams of protein and only 7 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises TV are ... The increasingly modern world of instantaneous consumption proves very convenient for businesses. With new ... oil and coal, which pollutes our air, water, and soil. It can also threaten ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, Inc. presented ... a VeinViewer® Vision vein finder for the nursing school simulation lab. ... and draw blood, combining technology with traditional technique. , “VeinViewer is a wonderful ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... In the ... forward. They’ll groom themselves to perfection, go out of their way to be romantic, ... – just take a look at any online dating profile. , A recent ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
Breaking Medicine Technology: